Because the aforementioned EGFR TKIs are therapeutically superior to the cytotoxic chemotherapy, the current standard of first-line care for patients with advanced EGFR-mutated NSCLC is the treatment with EGFR TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.